LOS ANGELES--(BUSINESS WIRE)--Zynx Health® today announced that it has published a new, publicly available review of vaccine administration guidelines specific to COVID-19 vaccines, including Pfizer/BioNTech BNT162b2, the COVID-19 vaccine co-developed by Pfizer and BioNTech, following its emergency use approval by the U.S. Food and Drug Administration (FDA). Concurrently, Zynx has published a comparison table spotlighting the primary characteristics of and differences between five COVID-19 vaccines in late-stage development.
The Zynx Health review of vaccine administration guidelines, drawn primarily from the Centers for Disease Control and Prevention and the most recent meeting of the FDA Advisory Committee on Immunization Practices, features detailed suggestions for hospital and health system operations staff and other healthcare providers as they develop a plan to administer an unprecedented number of vaccinations over the next year. The suggestions include the following:
- Prioritizing vaccine administration for healthcare personnel and residents of long-term care facilities.
- Potentially delaying vaccine administration in healthcare providers with documented acute SARS-CoV-2 (COVID-19) infection in the preceding 90 days.
- Potentially staggering vaccine delivery to healthcare providers in the same department or unit to limit staff shortages due to adverse postvaccination symptoms.
The review also notes that despite the increased risk for severe COVID-19 in pregnant women, safety and efficacy data of COVID-19 vaccines in women of childbearing potential are not currently available.
Zynx Health has also developed a new, easy-to-read COVID-19 vaccine comparison table, which includes information on vaccines (either already approved or in development) from the following companies:
- Pfizer/BioNTech
- Moderna
- Novavax
- AstraZeneca
- Johnson & Johnson
The table features specifics about each vaccine including FDA approval status, efficacy, side effects, storage, platform, age range, and administration route.
The vaccine administration guidelines and comparison data are available at no cost.
“With a COVID-19 vaccine now approved for emergency use, it’s of vital importance that hospitals and health systems are made aware of and adhere to the best-practice recommendations in the administration of these vaccines. We are proud to make this information available at no cost to do our small part in helping frontline healthcare workers effectively prepare for this immense undertaking,” said Chuck Tuchinda, MD, MBA, president of Zynx Health.
Zynx Health’s complimentary COVID-19 Vaccination Recommendations and COVID-19 Vaccine Comparison Table, as well as additional COVID-19 evidence-based content, are available at zynxhealth.com.
About Zynx Health
Zynx Health, a market leader in providing evidence- and experience-based clinical improvement solutions since 1996 and part of the Hearst Health network, provides healthcare professionals with vital information and processes that guide care decisions and reduce complexity across the entire patient journey in a way that leads to healthier lives for all. Zynx is a pioneer and market leader in evidence- and experience-based clinical solutions that help health systems improve patient outcomes, financial outcomes, clinical engagement, and technology performance. With Zynx Health, healthcare organizations exceed industry demands for delivering high-quality care at lower costs under value-based reimbursement models. To learn more, visit zynxhealth.com or call 888.996.9435. Follow Zynx Health on LinkedIn @Zynx-Health .
About Hearst Health
The mission of Hearst Health is to help guide the most important care moments by delivering vital information into the hands of everyone who touches a person’s health journey. Each year in the U.S., care guidance from Hearst Health reaches 85% of discharged patients, 205 million insured individuals, 103 million home health visits, and 3.2 billion dispensed prescriptions. The Hearst Health network includes FDB (First Databank), Zynx Health, MCG, Homecare Homebase, and MHK (formerly MedHOK). Hearst also holds a minority interest in the precision medicine and oncology analytics company M2Gen. Follow Hearst Health on Twitter @HearstHealth and LinkedIn @Hearst-Health.
